It was reported yesterday that Biosortia, a drug discovery company focused on natural microbiomes, has named Dr John Ryals as its new Director.
The new Director is the founder of Metabolon and has served as CEO and board member for 16 years. He has 30 years of experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. Prior to founding Metabolon, Dr Ryals was chief executive officer, president and founder of Paradigm Genetics Inc. He serves on the board of directors at AgBiome and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University.
Ross Youngs, Biosortia's Founder, Chairman and CEO, said, 'It is an honour to have Dr Ryals join the board of directors of Biosortia Pharmaceuticals. John has a proven track record of building professional and scientifically successful biotech companies. John is also a trailblazer who has advanced the understanding of human health with vision, strategy and operational excellence. Biosortia's business of drug discovery using unique capabilities to obtain the hidden drug-like chemistry of microbiome is complemented by Dr Ryals.'
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer